Pilot assessment of the antineoplastic drug contamination levels in British Columbian hospitals pre- and post-cleaning

Journal of Oncology Pharmacy Practice

Volumn 18, Issue 1, 2012, Pages 46-51

  Chu, Winnie C ^a   Hon, Chun Yip ^a,b   Danyluk, Quinn ^c   Chua, Prescillia P S ^c   Astrakianakis, George ^a,d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Vancouver Coastal Health   (Canada)

^c Fraser Health   (Canada)

^d Occupational Health and Safety Agency for Healthcare in British Columbia   (Canada)

Author keywords

Antineoplastic drugs; cleaning protocols; cyclophosphamide; hospital pharmacy; methotrexate; surface contamination

Indexed keywords

CYCLOPHOSPHAMIDE; METHOTREXATE;

CANADA; CLINICAL ASSESSMENT; DRUG CONTAMINATION; DRUG SYNTHESIS; HOSPITAL PHARMACY; HUMAN; LIMIT OF DETECTION; LIQUID CHROMATOGRAPHY; PILOT STUDY; PRIORITY JOURNAL; REVIEW; TANDEM MASS SPECTROMETRY;

ANTINEOPLASTIC AGENTS; BRITISH COLUMBIA; CHROMATOGRAPHY, LIQUID; CROSS-SECTIONAL STUDIES; CYCLOPHOSPHAMIDE; DRUG COMPOUNDING; ENVIRONMENTAL MONITORING; EQUIPMENT CONTAMINATION; HUMANS; METHOTREXATE; OCCUPATIONAL EXPOSURE; PHARMACY SERVICE, HOSPITAL; PILOT PROJECTS; TANDEM MASS SPECTROMETRY;

EID: 84857976090     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155211402106     Document Type: Review

References (26)

1. British Columbia Cancer Agency. 'Fact Sheet-March 2008' http://www.bccancer.bc.ca/NR/rdonlyres/352EEEBD-6405-4CEF-824A-89282CB83B1A/ 29390/BCCAFactSheet.pdf (accessed February 2010).
2. Some antineoplastic and immunosuppressive agents. Lyon, France: IARC ; 1981 :
3. Evaluation of carcinogenic risk to humans: pharmaceutical drugs. Lyon, France: IARC ; 1990 :
4. Some antiviral and antineoplastic drugs and other pharmaceutical agents. Lyon, France: IARC ; 1999 :
5. Alert document preventing occupational exposure to antineoplastic and other hazardous drugs in health care settings. Washington, DC: US Department of Health and Human Service, Public Occupational Safety and Health DHHS ; 2004 :
6. Canadian Institute for Health Information. Canada's Health Care ProvidersOttawa: CIHI, 2007, http://secure.cihi.ca/cihiweb/products/HCProviders- 07-EN-final.pdf (accessed February 2010).
7. Sessink PJ, Anzion RB, van der Broeck PH, et al. Detection of contamination with antineoplastic agents in a hospital pharmacy department. Pharm Weekbl Sci. 2003 ; 14: 16-22
8. Sessink PJ, Boer KA, Scheefhals AP, et al. Occupational exposure to antineoplastic agents at several departments in a hospital. Environmental contamination and excretion of cyclophosphamide and ifosfamide in urine of exposed workers. Int Arch Occup Environ Health. 1992 ; 64: 105-112
9. McDevitt JJ, Lees PS, McDiarmid MA. Exposure of hospital pharmacists and nurses to antineoplastic agents. J Occ Med. 1993 ; 35: 57-60 (Pubitemid 23018112)
10. Mader RM, Rizovski B, Steger GG, et al. Exposure of oncologic nurses to methotrexate in the treatment ofosteosarcoma. Arch Environ Health. 1996 ; 51: 310-314 (Pubitemid 26262466)
11. Connor TH, Anderson RW, Sessink PJ, et al. Surface contamination with antineoplastic agents in six cancer treatment centres in Canada and the United States. Am J Health-Sys Pharm. 1999 ; 56: 1427-1432 (Pubitemid 29331357)
12. Schmaus G, Schierl R, Funck S. Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry. Am J Health-Sys Pharm. 2002 ; 59: 956-961 (Pubitemid 34522598)
13. Pethran A, Schierl R, Hauff K. Uptake of antineoplastic agents in pharmacy and hospital personnel. Part 1: monitoring of urinary concentrations. Int Arch Occup Environ Health. 2003 ; 76: 5-10 (Pubitemid 36740714)
14. Fransman W, Vermueulen R, Kromhout H. Occupational dermal exposure to cyclophosphamide in Dutch hospitals: a pilot study. Ann Occ Hyg. 2004 ; 48 (3). 237-244 (Pubitemid 38520318)
15. Fransman W, Vermeulen R, Kromhout H. Dermal exposure to cyclophosphamide in hospitals during preparation, nursing and cleaning activities. Int Arch Occ Env Health. 2005 ; 78: 403412-403412
16. Sessink PJM, van de Kerkhof MCA, Anzion RB, et al. Environmental contamination and assessment of exposure to antineoplastic agents by determination of cyclophosphamide in urine of exposed pharmacy technicians: is skin absorption an important exposure route?. Arch Environ Health. 1994 ; 49: 165-169 (Pubitemid 24153799)
17. Sessink PJ, Timmersmans JL, Anzion RB, Bos RP. Assessment of occupational exposure of pharmaceutical plant workers to 5-fluorouracil: determination of alpha-fluoro-beta-alanine in urine. J Occup Med. 1994 ; 36 (1). 79-83 (Pubitemid 24020694)
18. Kromhout H, Hoek F, Uitterhoeve R, et al. Postulating a dermal pathway for exposure to antineoplastic drugs among hospital workers-applying a conceptual model to the results of three workplace surveys. Ann Occup Hyg. 2000 ; 44: 551-560
19. Sabatini L, Barbieri A, Tosi M, Violante FS. A new high-performance liquid chromatographic/electrospray ionization tandem mass spectrometric method for the simultaneous determination of cyclophosphamide, methotrexate and 5-fluorouracil as markers of surface contamination for occupational exposure. J Mass Spectrom. 2005 ; 40: 669-674 (Pubitemid 40733325)
20. Chu WC, Barnjak T British Columbia Healthcare Workplace Health, Safety & Wellness Conference. Kelowna, Canada: ; September 2007: 17-18.
21. Hornung RW, Reed LD. Estimation of average concentration in the presence of non-detectable values. Appl Occup Environ Health. 1990 ; 5: 46-51 (Pubitemid 20094575)
22. Connor T, Sessink P, Harrison B, et al. Surface contamination of chemotherapy drug vials and evaluation of new vial-cleaning techniques: results of three studies. Am J Health-Sys Pharm. 2005 ; 62: 475-484 (Pubitemid 40332257)
23. Bussieres J-F, Theoret Y, Prot-Labarthe S, Larocque D. Program to monitor surface contamination by methotrexate in a hematology-oncology satellite pharmacy. Am J Health-Sys Pharm. 2007 ; 64: 531-535 (Pubitemid 46339268)
24. Touzin K, Bussieres J-F, Langlois E, Lefebvre M. Evaluation of surface contamination in a hospital hematology-oncology pharmacy. J Oncol Pharm Practice. 2009 ; 15: 53-61
25. Schulz H, Bigelow S, Dobish R, Chambers CR. Antineoplastic agent workplace contamination study: The alberta cancer board pharmacy perspective. JOncol Pharm Practice. 2005 ; 11: 101-109 (Pubitemid 41488927)
26. International Agency for Research on Cancer. 'Summaries and Evaluations-Cyclophosphamide'http://www.inchem.org/documents/iarc/suppl7/ cyclophosphamide.html (accessed February 2010).